These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 126043)

  • 41. Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity.
    GANS H; KRIVIT W
    Ann Surg; 1962 Feb; 155(2):268-76. PubMed ID: 13896679
    [No Abstract]   [Full Text] [Related]  

  • 42. ACTIVATION OF THE BLOOD FIBRINOLYTIC ENZYME SYSTEM BY PLATELETS.
    REID WO; SILVER MJ
    Am J Physiol; 1964 Jun; 206():1255-61. PubMed ID: 14191030
    [No Abstract]   [Full Text] [Related]  

  • 43. Quantitative characterization of the binding of plasminogen to intact fibrin clots, lysine-sepharose, and fibrin cleaved by plasmin.
    Bok RA; Mangel WF
    Biochemistry; 1985 Jun; 24(13):3279-86. PubMed ID: 3161540
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of epsilon amino caproic acid, a fibrinolytic inhibitor, on implantation and fetal viability in the rat.
    Dubin NH; Cummings DB; Blake DA; King TM
    Biol Reprod; 1980 Oct; 23(3):553-7. PubMed ID: 6449964
    [No Abstract]   [Full Text] [Related]  

  • 45. The activation mechanism of human plasminogen.
    Rickli EE
    Thromb Diath Haemorrh; 1975 Nov; 34(2):386-95. PubMed ID: 128150
    [No Abstract]   [Full Text] [Related]  

  • 46. The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase.
    Urano T; Chibber BA; Castellino FJ
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4031-4. PubMed ID: 3473492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discreplasminin, a plasmin inhibitor isolated from Tityus discrepans scorpion venom.
    Brazón J; D'Suze G; D'Errico ML; Arocha-Piñango CL; Guerrero B
    Arch Toxicol; 2009 Jul; 83(7):669-78. PubMed ID: 19015833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator.
    Kaplan AP; Austen KF
    J Exp Med; 1972 Dec; 136(6):1378-93. PubMed ID: 4264575
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.
    Sangrar W; Gabel BR; Boffa MB; Walker JB; Hancock MA; Marcovina SM; Horrevoets AJ; Nesheim ME; Koschinsky ML
    Biochemistry; 1997 Aug; 36(34):10353-63. PubMed ID: 9265615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. THROMBOLYTIC THERAPY.
    DOUGLAS AS; MCNICOL GP
    Proc R Soc Med; 1964 Jul; 57(7):609-14. PubMed ID: 14178954
    [No Abstract]   [Full Text] [Related]  

  • 51. [THROMBOLYTIC THERAPY AND CHANGES IN FIBRINOLYTIC ACTIVITY].
    DOUGLAS AS; MCNICOL GP
    Recenti Prog Med; 1964 Sep; 37():189-217. PubMed ID: 14229145
    [No Abstract]   [Full Text] [Related]  

  • 52. Roles of individual kringle domains in the functioning of positive and negative effectors of human plasminogen activation.
    Menhart N; Hoover GJ; McCance SG; Castellino FJ
    Biochemistry; 1995 Feb; 34(5):1482-8. PubMed ID: 7849007
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasminogen interaction and activation on Streptococcus mutans surface.
    Urdaneta L; Vanegas G; Premoli G; Avilan L
    Oral Microbiol Immunol; 2004 Aug; 19(4):257-61. PubMed ID: 15209997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.
    Wang X; Lin X; Loy JA; Tang J; Zhang XC
    Science; 1998 Sep; 281(5383):1662-5. PubMed ID: 9733510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The lysis of arterial thrombi in rabbits and dogs by use of activated human plasminogen (fibrinolysin) (plasmin).
    GROSSI CE; CLIFFTON EE
    Surgery; 1955 May; 37(5):794-802. PubMed ID: 14373295
    [No Abstract]   [Full Text] [Related]  

  • 56. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kinetic studies of the urokinase-catalysed conversion of NH2-terminal glutamic acid plasminogen to plasmin.
    Christensen U
    Biochim Biophys Acta; 1977 Apr; 481(2):638-47. PubMed ID: 139931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The mechanism of activation of rabbit plasminogen by urokinase. Lack of a preactivation peptide.
    Sodetz JM; Brockway WJ; Mann KG; Castellino FJ
    Biochem Biophys Res Commun; 1974 Sep; 60(2):729-36. PubMed ID: 4278813
    [No Abstract]   [Full Text] [Related]  

  • 59. Binding of synthetic B knobs to fibrinogen changes the character of fibrin and inhibits its ability to activate tissue plasminogen activator and its destruction by plasmin.
    Doolittle RF; Pandi L
    Biochemistry; 2006 Feb; 45(8):2657-67. PubMed ID: 16489759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis.
    Suenson E; Lützen O; Thorsen S
    Eur J Biochem; 1984 May; 140(3):513-22. PubMed ID: 6233145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.